Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine

Amanda C. Cohn, Jessica R. MacNeil, Lee H. Harrison, Ruth Lynfield, Arthur Reingold, William Schaffner, Elizabeth R. Zell, Brian Plikaytis, Xin Wang, Nancy E. Messonnier, for the Active Bacterial Core Surveillance (ABCs) Team and MeningNet Surveillance Partners

Abstract

BACKGROUND: Meningococcal conjugate vaccines were licensed beginning in 2005 on the basis of serologic end points and recommended for use in adolescents. A single dose at age 11 to 12 years was expected to provide protection through late adolescence. We conducted a case-control evaluation of vaccine effectiveness (VE) and duration of protection of a meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D).

METHODS: Cases of culture- or polymerase chain reaction-confirmed serogroup A, C, W, and Y meningococcal disease among adolescents were identified through meningococcal disease surveillance sites in the United States from January 1, 2006, through August 31, 2013. Attempts were made to enroll 4 friend and school controls per case. VE was calculated using the generalized estimating equation, controlling for underlying medical conditions and smoking.

RESULTS: Serogroup C accounted for 88 (49%), serogroup Y 80 (44%), and serogroup W 13 (7%) of enrolled cases. Thirty-six (20%) cases and 87 (44%) controls received MenACWY-D. The overall VE estimate 0 to 8 years postvaccination was 69% (51% to 80%); VE was 79% (49% to 91%) at <1 year, 69% (44% to 83%) at 1 to <3 years, and 61% (25% to 79%) at 3 to <8 years. VE was 77% (57% to 88%) against serogroup C and 51% (1% to 76%) against serogroup Y.

CONCLUSIONS: MenACWY-D was effective in the first year after vaccination but effectiveness waned 3 to <8 years postvaccination. The estimates of VE from this evaluation informed the Advisory Committee on Immunization Practices in its decision to add a booster dose of MenACWY.

  • Accepted November 11, 2016.

 

FUENTE: http://pediatrics.aappublications.org/content/early/2017/01/16/peds.2016-2193?sso=1&sso_redirect_count=2&nfstatus=401

About The Author

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

2 × uno =